27.4 C
London
Thursday, August 11, 2022

MiroBio raises $97m Series B financing to develop checkpoint agonists for treatment of autoimmune diseases

Must read

MiroBio who are a leader in the development of checkpoint agonists to treat autoimmune diseases, have announced on Wednesday the completion of a $97m (£80m) Series B financing led by…

The post MiroBio raises $97m Series B financing to develop checkpoint agonists for treatment of autoimmune diseases appeared first on London Business News | Londonlovesbusiness.com.

 » Read More

Latest article